Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics

被引:0
作者
Miriam G. Mooij
Anne T. Nies
Catherijne A. J. Knibbe
Elke Schaeffeler
Dick Tibboel
Matthias Schwab
Saskia N. de Wildt
机构
[1] Erasmus MC-Sophia Children’s Hospital,Intensive Care and Department of Pediatric Surgery
[2] Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology,Faculty of Science
[3] University of Tuebingen,Hospital Pharmacy and Clinical Pharmacology
[4] Leiden Academic Centre for Research,Department of Clinical Pharmacology
[5] Pharmacology,undefined
[6] St. Antonius Hospital,undefined
[7] University Hospital Tuebingen,undefined
来源
Clinical Pharmacokinetics | 2016年 / 55卷
关键词
Morphine; Tramadol; Daptomycin; Bosentan; Adefovir Dipivoxil;
D O I
暂无
中图分类号
学科分类号
摘要
Membrane transporters play an essential role in the transport of endogenous and exogenous compounds, and consequently they mediate the uptake, distribution, and excretion of many drugs. The clinical relevance of transporters in drug disposition and their effect in adults have been shown in drug–drug interaction and pharmacogenomic studies. Little is known, however, about the ontogeny of human membrane transporters and their roles in pediatric pharmacotherapy. As they are involved in the transport of endogenous substrates, growth and development may be important determinants of their expression and activity. This review presents an overview of our current knowledge on human membrane transporters in pediatric drug disposition and effect. Existing pharmacokinetic and pharmacogenetic data on membrane substrate drugs frequently used in children are presented and related, where possible, to existing ex vivo data, providing a basis for developmental patterns for individual human membrane transporters. As data for individual transporters are currently still scarce, there is a striking information gap regarding the role of human membrane transporters in drug therapy in children.
引用
收藏
页码:507 / 524
页数:17
相关论文
共 50 条
  • [21] Orphan drug development: the increasing role of clinical pharmacology
    Ahmed, Mariam A.
    Okour, Malek
    Brundage, Richard
    Kartha, Reena V.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2019, 46 (05) : 395 - 409
  • [22] Optimizing Drug Development: Harnessing the Sustainability of Pharmaceutical Cocrystals
    Aitipamula, Srinivasulu
    Bolla, Geetha
    MOLECULAR PHARMACEUTICS, 2024, 21 (07) : 3121 - 3143
  • [23] Curious Discoveries in Antiviral Drug Development: The Role of Serendipity
    De Clercq, Erik
    MEDICINAL RESEARCH REVIEWS, 2015, 35 (04) : 698 - 719
  • [24] Physiologically Based Pharmacokinetic (PBPK) Model Predictions of Disease Mediated Changes in Drug Disposition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)
    Adiwidjaja, Jeffry
    Spires, Jessica
    Brouwer, Kim L. R.
    PHARMACEUTICAL RESEARCH, 2024, 41 (03) : 441 - 462
  • [25] Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)
    Matic, Maja
    Nijenhuis, Marga
    Soree, Bianca
    de Boer-Veger, Nienke J.
    Buunk, Anne-Marie
    Houwink, Elisa J. F.
    Mulder, Hans
    Rongen, Gerard A. P. J. M.
    van der Weide, Jan
    Wilffert, Bob
    Swen, Jesse J.
    Guchelaar, Henk-Jan
    Deneer, Vera H. M.
    van Schaik, Ron H. N.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2022, 30 (10) : 1105 - 1113
  • [26] Development of a GC-MS Method for the Analysis of Selected Opioids in Human Hair Samples
    Soltaninejad, Kambiz
    Shiri-Ghaleh, Vida
    Koohi, Mohammad Kazem
    Hassan, Jalal
    INTERNATIONAL JOURNAL OF MEDICAL TOXICOLOGY AND FORENSIC MEDICINE, 2024, 14 (03):
  • [27] Effects of chronic mild stress on the development of drug dependence in rats
    Papp, Mariusz
    Gruca, Piotr
    Lason-Tyburkiewicz, Magdalena
    Litwa, Ewa
    Willner, Paul
    BEHAVIOURAL PHARMACOLOGY, 2014, 25 (5-6): : 518 - 531
  • [28] Antibacterial drug development program successes and failures: a pharmacometric explanation
    Ambrose, Paul G.
    CURRENT OPINION IN PHARMACOLOGY, 2017, 36 : 1 - 7
  • [29] Incorporating the assessment of abuse liability into the drug discovery and development process
    Mansbach, RS
    Feltner, DE
    Gold, LH
    Schnoll, SH
    DRUG AND ALCOHOL DEPENDENCE, 2003, 70 (03) : S73 - S85
  • [30] Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome
    Rickli, Anna
    Liakoni, Evangelia
    Hoener, Marius C.
    Liechti, Matthias E.
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (03) : 532 - 543